USFDA approves Eli Lilly's Trulicity (dulaglutide) for reduction in MACE in type 2 diabetes patient Medical Dialogues Bureau23 Feb 2020 12:00 PM ISTNew indication reflects a distinct patient population in the REWIND study, including primary people with multiple cardiovascular risk factors but...